ArticleJournal of gastrointestinal oncology2026
Efficacy and safety of modified FLOT chemotherapy in gastric or gastroesophageal junction adenocarcinoma: a retrospective cohort study.
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) is the standard treatment for resectable gastric and gastroesophageal junction (GEJ) adenocarcinoma, with fluorouracil administered at 2,600 mg/m Methods: We conducted a retrospective cohort study of patients with resectable gastric or GEJ adenocarcinoma treated with predefined, modified perioperative FLOT at three institutions between 2019 and 2025. The regimen consisted of fluorouracil 2,400 mg/m Results: Twenty-nine patients were included (median age 66 years; 62% male; 59% gastric and 34% GEJ tumors). Curative-intent resection was achieved in 86% of patients, with an R0 resection rate of 88% and a pathological complete response (pCR) rate of 16%. At a median follow-up of 30.3 months, median overall survival (OS) was 53.6 months (3-year OS 75.3%), and median recurrence-free survival (RFS) was 46.1 months (3-year RFS 52.4%). Grade 3 or higher neutropenia occurred in 34% of patients, and infections in 10%; no treatment-related deaths were observed. Conclusions: In this multi-institutional, real-world cohort, modified perioperative FLOT was associated with acceptable treatment delivery, manageable toxicity, and favorable clinical outcomes in selected patients with resectable gastric and GEJ adenocarcinoma. These findings support the feasibility of dose-modified FLOT in routine clinical practice, particularly for patients at risk for treatment-related toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.